BioCentury
ARTICLE | Clinical News

Mereo starts Phase IIb for osteogenesis imperfecta

May 12, 2017 8:05 PM UTC

Mereo BioPharma Group plc (LSE:MPH) began the Phase IIb ASTEROID trial to evaluate BPS-804 to treat osteogenesis imperfecta. The double-blind, placebo-controlled, international trial will enroll up to 120 patients to receive 1 of 3 doses of IV BPS-804.

The trial will evaluate the change in trabecular volumetric bone mineral density (BMD) and bone strength as its co-primary endpoints. The trial will also evaluate quality of life (QOL) and changes in lumbar, whole body and proximal femur BMD. Top-line data are expected in mid-2018...

BCIQ Company Profiles

Mereo BioPharma Group plc

BCIQ Target Profiles

Sclerostin